Compare Pfizer with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs IPCA LABS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER IPCA LABS PFIZER/
IPCA LABS
 
P/E (TTM) x 33.9 24.7 136.9% View Chart
P/BV x 5.8 5.0 115.4% View Chart
Dividend Yield % 0.6 0.2 244.3%  

Financials

 PFIZER   IPCA LABS
EQUITY SHARE DATA
    PFIZER
Mar-19
IPCA LABS
Mar-19
PFIZER/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,8401,042 368.5%   
Low Rs2,080590 352.5%   
Sales per share (Unadj.) Rs455.0298.6 152.4%  
Earnings per share (Unadj.) Rs93.835.0 267.9%  
Cash flow per share (Unadj.) Rs109.449.4 221.3%  
Dividends per share (Unadj.) Rs22.503.00 750.0%  
Dividend yield (eoy) %0.80.4 206.8%  
Book value per share (Unadj.) Rs658.2247.1 266.4%  
Shares outstanding (eoy) m45.75126.35 36.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x6.52.7 238.1%   
Avg P/E ratio x31.623.3 135.4%  
P/CF ratio (eoy) x27.116.5 163.9%  
Price / Book Value ratio x4.53.3 136.2%  
Dividend payout %24.08.6 279.9%   
Avg Mkt Cap Rs m135,420103,108 131.3%   
No. of employees `0002.613.4 19.6%   
Total wages/salary Rs m3,2387,874 41.1%   
Avg. sales/employee Rs Th7,911.42,807.0 281.8%   
Avg. wages/employee Rs Th1,230.9585.8 210.1%   
Avg. net profit/employee Rs Th1,630.7329.0 495.7%   
INCOME DATA
Net Sales Rs m20,81537,732 55.2%  
Other income Rs m1,674577 290.2%   
Total revenues Rs m22,48938,309 58.7%   
Gross profit Rs m5,7126,901 82.8%  
Depreciation Rs m7141,824 39.1%   
Interest Rs m73189 38.6%   
Profit before tax Rs m6,5995,465 120.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,3091,042 221.5%   
Profit after tax Rs m4,2914,422 97.0%  
Gross profit margin %27.418.3 150.0%  
Effective tax rate %35.019.1 183.4%   
Net profit margin %20.611.7 175.9%  
BALANCE SHEET DATA
Current assets Rs m27,16723,778 114.3%   
Current liabilities Rs m8,91710,975 81.2%   
Net working cap to sales %87.733.9 258.4%  
Current ratio x3.02.2 140.6%  
Inventory Days Days68104 65.4%  
Debtors Days Days3066 45.7%  
Net fixed assets Rs m8,86220,368 43.5%   
Share capital Rs m458253 181.0%   
"Free" reserves Rs m29,65630,971 95.8%   
Net worth Rs m30,11331,224 96.4%   
Long term debt Rs m251,409 1.8%   
Total assets Rs m39,40045,507 86.6%  
Interest coverage x91.530.0 305.5%   
Debt to equity ratio x00 1.8%  
Sales to assets ratio x0.50.8 63.7%   
Return on assets %11.110.1 109.3%  
Return on equity %14.214.2 100.6%  
Return on capital %22.117.3 127.8%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m42817,308 2.5%   
Fx outflow Rs m7866,266 12.5%   
Net fx Rs m-35811,042 -3.2%   
CASH FLOW
From Operations Rs m9784,923 19.9%  
From Investments Rs m351-1,563 -22.5%  
From Financial Activity Rs m-1,099-1,832 60.0%  
Net Cashflow Rs m2311,528 15.1%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 4.9 25.3 19.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.4 136.2%  
Shareholders   85,207 36,892 231.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare PFIZER With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Mar 27, 2020 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS